hVIVO plc

Equities

HVO

GB00B6ZM0X53

Healthcare Facilities & Services

Delayed London S.E. Other stock markets			5-day change	1st Jan Change
- ^GBX	-.--%		+18.92%	+41.94%

Feb. 14	Hvivo Completes Secondary Placing	MT
Feb. 14	Hvivo Shareholders Plan Secondary Placing to Sell 14 Million Shares	MT

HVIVO signs second bespoke human challenge model contract in as many months

July 25, 2023 at 07:40 am EDT

(via NewsDirect)

hVIVO PLC (AIM:HVO) chief executive Mo Khan speaks to Thomas Warner from Proactive after announcing that the specialist contract research organisation has begun work on a new Flu B human challenge model as part of a new deal with an existing "large pharma" client company. Khan lays out the timeline for the rest of the work on the contract, suggesting that the "whole manufacturing process" should be complete by the end of Q3, at which point a characterisation study will begin.

He adds that if the characterisation study is successful then he hopes the "full blown" human challenge trial can begin in the new year. Khan goes on to describe the potential impact of the model as "quite significant", highlighting some additional funding from the client to help expedite the process. He concludes by saying that hVIVO "is here to build new challenge models to be able to test new drugs and bring new vaccines to the market... overall we are very happy that we're adding a new human challenge model [and] very happy that we're continuing to help our current clients in bringing vaccines to market faster."

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Latest news about hVIVO plc

Hvivo Completes Secondary Placing	Feb. 14	MT
Hvivo Shareholders Plan Secondary Placing to Sell 14 Million Shares	Feb. 14	MT
Hvivo Wins GBP6 Million Antiviral Testing Contract	Jan. 02	MT
Hvivo Secures GBP17 Million Contract for RSV Antiviral Drug Testing; Stock Surges	Dec. 13	MT
Earnings Flash (HVO.L) HVIVO Reports H1 Revenue GBP27.3M	23-09-12	MT
Earnings Flash (HVO.L) HVIVO Posts H1 EPS GBX0.58	23-09-12	MT
HVIVO Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-12	CI
Lab Services Company Hvivo to Build New London Facility	23-08-29	MT
HVIVO plc Plans for A New Facility to Meet Growing Demand	23-08-29	CI
Hvivo Wins GBP13 Million Contract from Global Pharma Client	23-07-25	MT
HVIVO Surges 10% on GBP7 Million RSV Drug Testing Contract With Asian Pacific Drugmaker	23-02-06	MT
UK's hVIVO Signs GBP2.5 Million Contract for RSV Vaccine Candidate Testing	23-01-04	MT
HVIVO Up 9% With $16 Million Antiviral Testing Contract	22-11-10	MT
HVIVO Announces £10.4 Million Contract with Existing Big Pharma Client	22-08-22	CI
Cocrystal Pharma Engages hVIVO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344	22-08-08	CI
HVIVO Limited Signs £6.2 Million Influenza Human Challenge Study Contract	22-08-04	CI
Hvivo Signs £7.2 Million Contract with an Existing Top 5 Global Pharmaceutical Company to Test Its Orally Administered Antiviral Product	22-06-14	CI
HVIVO Signs GBP 14.7 Million Influenza Contract	22-06-01	CI
HVIVO Signs a £7.3 Million Influenza Human Challenge Study Contract Win	22-05-18	CI
HVIVO Receives New Study with an Existing Big Pharma Client to Act as A Vaccination Site for A Phase II Field Study	22-05-05	CI
HVIVO Signs Substantial Contract with an Existing Top 5 Global Pharmaceutical Client to Manufacture Virus for Use in Human Challenge Studies	22-05-04	CI
HVIVO Wins £5 million RSV Human Challenge Study Contract	22-03-25	CI
HVIVO Announces Positive Results from RSV Human Challenge Study	22-02-17	CI
HVIVO Signs £5 Million Influenza Human Challenge Study Contract with a Biotech Company	21-12-21	CI
Hvivo Limited Signs $13.4 Million Contract with A US-Based Biotechnology Company to Test Its Novel Antiviral Candidate Using the Hvivo Influenza Human Challenge Study Model	21-12-10	CI

Chart hVIVO plc

Duration

Period

More charts

Company Profile

hVIVO plc, formerly Retroscreen Virology Group plc, is a holding company. The Company is engaged in a life sciences business pioneering a technology platform of human disease models to accelerate drug discovery and development in respiratory and infectious diseases, including flu, respiratory syncytial virus (RSV), asthma and common cold. It has commercialized approximately four disease models, enrolled over 2,000 subjects and conducted approximately 40 product validation studies for a range of industry, government and academic clients and collaborators. The Company offers services, such as challenge study services, lab services, and target and biomarker discovery. It offers viral challenge studies in healthy volunteers in influenza, human rhinovirus (HRV) and RSV. Its lab services include assay development, transfer and optimization across the immunological, molecular and cell-based assay platforms, including offering options in sample matrix testing and specialty biomarker assays.

Sector

Healthcare Facilities & Services

More about the company

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
HVIVO PLC	+41.94%	18.04M
CVS HEALTH CORPORATION	-14.92%	84.68B
HCA HEALTHCARE, INC.	+13.30%	81.12B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+10.92%	29.4B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-12.71%	16.73B
FRESENIUS SE & CO. KGAA	-3.06%	16.36B
QUEST DIAGNOSTICS INCORPORATED	-2.63%	14.92B
EUROFINS SCIENTIFIC SE	-3.97%	11.66B
FRESENIUS MEDICAL CARE AG	-1.42%	11.72B
PURE HEALTH HOLDING	-31.75%	11.77B

Other Healthcare Facilities & Services